HIV Drug Resistance Early Warning Indicators in Cohorts of Individuals Starting Antiretroviral Therapy Between 2004 and 2009: World Health Organization Global Report From 50 Countries
| Autor: | Diane E Bennett, Ahmed Saadani, Giovanni Ravasi, Karen F. Kelley, Michael R. Jordan, James H McMahon, Silvia Bertagnolio, Steven Y. Hong |
|---|---|
| Rok vydání: | 2012 |
| Předmět: |
Adult
Microbiology (medical) medicine.medical_specialty Pediatrics Population Supplement Articles HIV Infections Pharmacy World Health Organization Cohort Studies Drug Resistance Viral Health care medicine Humans Lost to follow-up Child education Developing Countries education.field_of_study business.industry Public health Drug holiday Regimen Infectious Diseases Anti-Retroviral Agents Population Surveillance Emergency medicine Patient Compliance Lost to Follow-Up business Delivery of Health Care HIV drug resistance |
| Zdroj: | Clinical Infectious Diseases. 54:S280-S289 |
| ISSN: | 1537-6591 1058-4838 |
| DOI: | 10.1093/cid/cis207 |
| Popis: | The rapid scale-up of antiretroviral therapy (ART) for human immunodeficiency virus (HIV) in resource-limited settings (RLSs) is an international healthcare priority. By December 2010, 6.6 million people living with HIV in low- and middle-income countries were receiving ART, representing an increase of >1.4 million people from December 2009 and a 22-fold increase in 10 years [1]. The public health approach to scaling up ART in RLSs includes standardized and simplified treatment regimens consistent with international standards and appropriate to local circumstances [2]. Treatment of millions of HIV-infected patients will inevitably be accompanied by the emergence and transmission of HIV drug resistance (HIVDR). The human and financial implications of HIVDR are significant; HIVDR limits treatment options and necessitates switching to second-line regimens that produce more long-term toxicity [3–6]. Moreover, the annual cost of a second-line protease inhibitor–based regimen is 4–8 times higher than that of currently recommended first-line nonnucleoside reverse transcriptase inhibitor (NNRTI)–based regimens [7]. Although the proportion of patients on second-line ART is currently small in most RLSs ( |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|